Oncimmune (LON:ONC) issued its quarterly earnings data on Tuesday. The company reported GBX (5.70) (($0.08)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The company had revenue of £800 million for the quarter. Oncimmune had a negative net margin of 2,521.78% and a negative return on equity of 81.75%.

Shares of Oncimmune (ONC) opened at GBX 145.50 ($2.01) on Thursday. The firm has a market cap of $88.48 and a PE ratio of -1,455.00. Oncimmune has a 1 year low of GBX 100 ($1.38) and a 1 year high of GBX 150 ($2.07).

ONC has been the topic of a number of recent research reports. Bryan, Garnier & Co upped their target price on shares of Oncimmune from GBX 154 ($2.13) to GBX 168 ($2.32) and gave the stock a “buy” rating in a research report on Tuesday. Berenberg Bank initiated coverage on shares of Oncimmune in a research report on Friday, January 19th. They issued a “buy” rating and a GBX 169 ($2.33) target price on the stock.

COPYRIGHT VIOLATION WARNING: “Oncimmune (ONC) Issues Earnings Results” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/15/oncimmune-onc-issues-earnings-results.html.

Oncimmune Company Profile

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.